Absci/$ABSI
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Absci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Ticker
$ABSI
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
157
ISIN
US00091E1091
Website
Absci Metrics
BasicAdvanced
$343M
-
-$0.92
2.20
-
Price and volume
Market cap
$343M
Beta
2.2
52-week high
$6.33
52-week low
$2.01
Average daily volume
3.3M
Financial strength
Current ratio
5.717
Quick ratio
4.962
Long term debt to equity
2.357
Total debt to equity
4.486
Interest coverage (TTM)
-238.72%
Profitability
EBITDA (TTM)
-98.674
Gross margin (TTM)
-1,282.91%
Net profit margin (TTM)
-2,232.13%
Operating margin (TTM)
-2,320.23%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-27.53%
Return on equity (TTM)
-48.98%
Valuation
Price to revenue (TTM)
65.089
Price to book
1.73
Price to tangible book (TTM)
2.22
Price to free cash flow (TTM)
-4.08
Free cash flow yield (TTM)
-24.51%
Free cash flow per share (TTM)
-65.92%
Growth
Revenue change (TTM)
-9.95%
Earnings per share change (TTM)
-20.58%
3-year revenue growth (CAGR)
1.99%
3-year earnings per share growth (CAGR)
-19.64%
What the Analysts think about Absci
Analyst ratings (Buy, Hold, Sell) for Absci stock.
Bulls say / Bears say
Absci's AI-driven platform can design antibodies to precisely target an epitope with optimized interface contacts to ensure high potency and affinity, setting itself apart from competitors. (tipranks.com)
Absci has struck multiple pharma deals and achieved key design milestones, validating its technology and likely attracting further partnerships. (tipranks.com)
Absci had approximately $112M in cash and cash equivalents at the end of 4Q24 and raised approximately $40M in equity funding since then, resulting in a pro forma cash balance of $152M. (tipranks.com)
For 4Q24, the company reported revenues of $0.7M, which was below the consensus estimate of $1.8M, and a net loss of $0.25 per share, compared to the consensus estimated net loss of $0.22 per share. (tipranks.com)
Q4 revenues of $0.7M brought FY24 total revenues to $4.5M, below expectations. (tipranks.com)
Absci's net margin excels beyond industry benchmarks, reaching -1610.7%. This signifies efficient cost management and strong financial health. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
Absci Financial Performance
Revenues and expenses
Absci Earnings Performance
Company profitability
Absci News
AllArticlesVideos
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
GlobeNewsWire·2 months ago
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
GlobeNewsWire·2 months ago
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Absci stock?
Absci (ABSI) has a market cap of $343M as of July 03, 2025.
What is the P/E ratio for Absci stock?
The price to earnings (P/E) ratio for Absci (ABSI) stock is 0 as of July 03, 2025.
Does Absci stock pay dividends?
No, Absci (ABSI) stock does not pay dividends to its shareholders as of July 03, 2025.
When is the next Absci dividend payment date?
Absci (ABSI) stock does not pay dividends to its shareholders.
What is the beta indicator for Absci?
Absci (ABSI) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.